Clinical trials: Connective Tissue Disorders
Mucopolysaccharidosis Type IIIB, MPS IIIB (Sanfilippo B Syndrome)
Early Access Treatment With Tralesinidase Alfa in Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B)
This is an intermediate-size patient population Early Access Program (EAP) providing access to intracerebroventricular (ICV) tralesinidase alfa (TA) for participants with mucopolysaccharidosis type IIIB (MPS IIIB, Sanfilippo…
- Trial name
- EAP (NCT07733856)
- Testing
- Tralesinidase alfa (TA)
- Where
- United States
- Sponsor
- Spruce Biosciences
Triple Negative Breast Cancer (TNBC), Colorectal Cancer
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific…
- Conditions
- Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer
- Trial name
- CT-202 (NCT07545122)
- Testing
- CT-202
- Where
- 6 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Context Therapeutics Inc.
Malignant Melanoma
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who…
- Trial name
- NCT03178851
- Testing
- Atezolizumab, Cobimetinib
- Where
- 43 sites in United States, Australia and 5 more
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Uterine Fibroids, Endometriosis
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in…
- Trial name
- NCT05862272
- Testing
- Relugolix Combination Tablet
- Where
- 120 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Skin Diseases, Infection
Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects
The main purpose of this study is to compare the safety and efficacy of tigecycline versus clindamycin (including subjects treated with vancomycin) in pediatric subjects (aged 8 to 17 years) with complicated skin and skin…
- Trial name
- NCT00911573
- Testing
- Tigecycline, Clindamycin (or Vancomycin if needed)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasms, Breast
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
This is a Phase II, randomized, open-label, multi-center study evaluating the efficacy and safety of lapatinib in combination with chemotherapy versus trastuzumab in combination with chemotherapy in women with HER2-positive and…
- Trial name
- NCT01137994
- Testing
- Lapatinib, Trastuzumab, Docetaxel
- Sponsor
- GlaxoSmithKline
Psoriasis
Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.
- Trial name
- NCT00975637
- Testing
- 70 mg SC, 210 mg SC, 140 mg SC
- Volunteers
- 198 people
- Sponsor
- Bausch Health Americas, Inc.
Malignant Melanoma
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
- Trial name
- CheckMate218 (NCT02186249)
- Testing
- Nivolumab, Ipilimumab
- Where
- 66 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Applications for Methotrexate Optimization in Rheumatoid Arthritis
The goal of this study is to enable the study sponsor to assess the impact of a marketed or validated blood test has on physicians' clinical treatment decision making when treating RA patients who have been taking methotrexate.
- Trial name
- AMORA (NCT01038349)
- Testing
- Avise PG - Diagnostic test
- Volunteers
- 256 people
- Sponsor
- Cypress Bioscience, Inc.
Breast Cancer
A Pilot Study on Use of Liquid Crystal Contact Thermography to Detect Early Breast Cancer
The study was a multicentre, observational, cross-sectional, open and monitored trial involving 274 females who were subject to an examination using liquid crystal contact thermography device as a complementary tool to standard…
- Trial name
- NCT03858738
- Testing
- Thermographic breast examination performed by Braster device
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Braster S.A.
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Cold Sores
An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores
Focus Consumer Healthcare has developed Herpecin L. Herpecin L combines many different ingredients hypothesized to promote quick healing and symptom reduction from cold sores.
- Trial name
- NCT05796635
- Testing
- Herpecin L
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Focus Consumer Healthcare
Mesothelioma, Bladder Cancer
Safety Study of MGD009 in B7-H3-expressing Tumors
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely.
- Conditions
- Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02628535
- Testing
- MGD009
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 67 people
- Sponsor
- MacroGenics
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02326740
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 9 people
- Sponsor
- XOMA (US) LLC
Metastatic Breast Cancer
A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims…
- Trial name
- NCT05141240
- Testing
- Ribiciclib, Palbociclib, Abemaciclib
- Where
- United States
- Volunteers
- 4,650 people
- Sponsor
- Novartis Pharmaceuticals
Transepidermal Water Loss, Erythema
Skin Protectant Properties of Omeza Collagen Matrix on Damaged Skin
Single-blind within subject comparison study conducted to investigate the skin protectant properties of Omeza Collagen Matrix on damaged skin
- Trial name
- NCT04512274
- Testing
- Test Article
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Omeza, LLC
GIST, Gastrointestinal Stromal Tumors
Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
The purpose of this trail is to evaluate the performance of Genetron D842V PCR kit in GIST patients using real-time PCR method.
- Trial name
- NCT05400018
- Where
- 3 sites in China
- Volunteers
- 1,041 people
- Sponsor
- Genetron Health
Psoriasis
A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects
GSK2894512 (trans-isomer) is a fully synthetic, non-steroidal anti-inflammatory agent. This study is being conducted to evaluate the PK, safety and tolerability of GSK2894512 cream, 1 percent administered topically to healthy…
- Trial name
- NCT03201978
- Testing
- GSK2894512 1% CREAM, GSK2894512 MATCHING VEHICLE CREAM
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dermatitis, Atopic
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity [atopic dermatitis severity index {ADSI} scoring] and perceived benefits in itch [visual analog score {VAS}…
- Trial name
- NCT05226143
- Testing
- Gel Cream
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Melanoma, Solid Tumors
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors
This Phase Ib/II study is a clinical study to explore the efficacy and safety of BL-M08D1 for injection in patients with locally advanced or metastatic melanoma and other solid tumors.
- Trial name
- NCT07841925
- Testing
- BL-M08D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.